QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

- - -

Vol / Avg.

-/31.4K

Div / Yield

-

52 Wk

19.89 - 63.69

Mkt Cap

570.3M

Payout Ratio

-

Open

-

P/E

-

EPS

-0.76

Shares

20.7M

Outstanding

20.7M

Total Float

8.9M

Analyst Ratings

Oppenheimer Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $55

Benzinga - 6 days ago

Tarsus Pharmaceuticals Q3 EPS $(0.76) Up From $(3.71) YoY, Sales $1.24M

Benzinga - Nov 9, 2021, 4:56PM

Tarsus Pharmaceuticals, Inc. Presents Data From Two Pioneering Studies On The Prevalence And Impact Of Demodex Blepharitis At The American Academy Of Optometry 2021 Annual Meeting

Benzinga - Nov 4, 2021, 9:46AM

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference Nov. 8

Benzinga - Nov 2, 2021, 5:35PM

Raymond James Maintains Strong Buy on Tarsus Pharmaceuticals, Raises Price Target to $65

Benzinga - Oct 8, 2021, 4:42AM

Tarsus Pharmaceuticals Q2 EPS $0.29

Benzinga - Aug 4, 2021, 5:40PM

Tarsus Pharma Late Saturday Highlighted Presentation Of New Saturn-1 Trial Data, Titan Real-World Prevalence Study Results At American Society of Cataract and Refractive Surgery Meeting

Benzinga - Jul 26, 2021, 9:59AM

Raymond James Maintains Strong Buy on Tarsus Pharmaceuticals, Raises Price Target to $50

Benzinga - Jun 29, 2021, 7:16AM

Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study

Benzinga - Jun 21, 2021, 7:33AM

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis; Co. Reports 'Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints'

Benzinga - Jun 21, 2021, 6:04AM

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease

Benzinga - Jun 16, 2021, 4:06PM

Tarsus Pharmaceuticals Q1 EPS $0.47 Up From $(0.74) YoY, Sales $33.43M

Benzinga - May 11, 2021, 4:22PM

UPDATE: Tarsus Says Topline Data From Saturn-1 Trial Expected In Jul. 2021

Benzinga - May 6, 2021, 4:52PM

Tarsus Pharma Reports Initiation Of Saturn-2 Pivotal Phase 3 Trial Evaluating Safety, Efficacy Of TP-03 For Treatment Of Demodex Blepharitis

Benzinga - May 6, 2021, 4:51PM

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance Of Investigational New Drug Application For TP-05 For Lyme Disease Prevention

Benzinga - May 4, 2021, 4:14PM

Tarsus Pharmaceuticals Announces A Strategic Partnership With LianBio In March 2021 For TP-03 In Greater China Provides Tarsus With $70M Expected During The Next 12 Months

Benzinga - Mar 31, 2021, 4:19PM

Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases

Benzinga - Mar 30, 2021, 7:14AM

Tarsus Pharmaceuticals And LianBio Announce A Strategic Partnership To Develop And Commercialize Its TP-03 In China For The Treatment Of Demodex Blepharitis And Meibomian Gland Disease

Benzinga - Mar 29, 2021, 4:19PM

Tarsus Pharmaceuticals And LianBio Announce Strategic Partnership To Develop And Commercialize TP-03 In Greater China For Treatment Of Demodex Plepharitis And Meibomian Glad Disease

Benzinga - Mar 29, 2021, 4:07PM

Tarsus Pharma Reports Type C Meeting With FDA Related To New Drug Application Submission Requirements For TP-03

Benzinga - Dec 23, 2020, 7:06AM

load more

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		-0.430		-0.760		-0.3300
REV		5.330M		1.240M		-4.090M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Tarsus Pharmaceuticals Questions & Anwsers

Q

How do I buy Tarsus Pharmaceuticals (TARS) stock?

A

You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Tarsus Pharmaceuticals's (TARS) competitors?

A

There are no as such competitors for Tarsus Pharmaceuticals.

Q

What is the target price for Tarsus Pharmaceuticals (TARS) stock?

A

The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Oppenheimer on November 23, 2021. The analyst firm set a price target for 55.00 expecting TARS to rise to within 12 months (a possible 99.42% upside). 3 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Tarsus Pharmaceuticals (TARS)?

A

The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $27.58 last updated Mon Nov 29 2021 21:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Tarsus Pharmaceuticals (TARS) pay a dividend?

A

There are no upcoming dividends for Tarsus Pharmaceuticals.

Q

When is Tarsus Pharmaceuticals (NASDAQ:TARS) reporting earnings?

A

Tarsus Pharmaceuticals’s $Q3 earnings are confirmed for after-market on November 9, 2021.

Q

Is Tarsus Pharmaceuticals (TARS) going to split?

A

There is no upcoming split for Tarsus Pharmaceuticals.

Q

What sector and industry does Tarsus Pharmaceuticals (TARS) operate in?

A

Tarsus Pharmaceuticals is in the sector and industry. They are listed on the NASDAQ.